Investor Presentaiton
Income Statement
Year Ended 31 December
(1,294.7)
Revenue
In 2020, we generated total revenue of RMB3,843.8
million, including RMB2,367.5 million driven by product
sales; coupled with RMB1,476.3 million from License fee
and service income
Expenses
R&D investments were spending on progressing clinical
trials of late-stage and prioritized assets towards our
robust pipeline globally
The planned increase in S&M expenses was due to
broader commercialisation activities with respect to
TYVYTⓇ(sintilimab injection), BYVASDAⓇ (bevacizumab
biosimilar), SULINNOⓇ (adalimumab biosimilar) and
HALPRYZAⓇ(rituximab biosimilar)
IFRS loss for the year
IFRS loss for the year was RMB998.4 million
Non-IFRS loss for the year
Adjustments to IFRS measure was driven by non-cash
item namely share-based compensation expenses
RMB'million
Revenue
Cost of sales
Gross profit (IFRS Measure)
Other income
Research and development expenses
Administrative and other expenses
2020
2019
3,843.8
1,047.5
(387.8)
(124.9)
3,456.0
922.6
246.8
144.1
(1,851.5)
(436.9)
(255.3)
Selling and marketing expenses
(1,340.9)
(692.5)
Royalties and other related payments
(384.1)
(499.7)
Other gains and losses
(480.0)
15.2
Finance costs
(68.4)
(59.5)
Income tax expense
(139.7)
Loss for the year (IFRS Measure)
(998.4)
(1,719.9)
Adjustments to Non-IFRS measure
402.5
148.1
(595.9)
(1,571.8)
Loss for the year (Non-IFRS Measure)
Note: Numbers may not add due to rounding
Innovent
Confidential
Copyright©2021 Innovent Biologics
36View entire presentation